In the context that H1A does not interrupt PD-1 binding to PD-L1 (Supplemental Figure 8A), these results clearly support an exciting conclusion that targeting the tumor-intrinsic function of PD-L1 could provide extra benefits when combined with immune checkpoint blockade reagents. Here, CD274 is linked to neoplasm.